Climb Bio (CLYM) Other financing activities (2024 - 2026)

Climb Bio's (CLYM) quarterly Other financing activities came in at $5000.0 in Q1 2026, down 100.0% on a QoQ basis from $108.8 million in Q4 2024.

Climb Bio (CLYM) Other financing activities (2024 - 2026) Analysis & Trends

Climb Bio (CLYM) has 2 years of Other financing activities data on file, last reported at $5000.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5000.0 (down 100.0% YoY) and the FY2024 annual result came in at $119.8 million, changed N/A from the prior year.
Other financing activities eased to $5000.0 in Q1 2026, from $108.8 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $119.7 million in Q2 2024 to a low of $5000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Climb Bio	1.24 Bn	1.24 Bn	-

Download Data